Renal Cancer
Epigenetic modification of Castor zinc finger 1 (CASZ1) is associated with tumor microenvironments and prognosis of clear cell renal cell carcinoma.
September 6, 2024
Clinical Outcomes for Metastatic Renal Cell Carcinoma (mRCC) Patients Ineligible for Front-line Clinical Trials.
September 5, 2024
Phase II Trial of Intermittent Therapy in Patients with Metastatic Renal Cell Carcinoma Treated with Front-line Ipilimumab and Nivolumab.
September 5, 2024
Randomized phase 2 dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma.
September 5, 2024
Renal cell carcinoma: entering the age of biomarkers.
September 4, 2024
Prognostic Role of Pre-Treatment Body Composition Parameters in Patients Undergoing First-Line Immunotherapy for Metastatic Renal Cell Carcinoma.
September 4, 2024
Salvage stereotactic ablative body radiotherapy after thermal ablation of primary kidney cancer.
August 30, 2024
Contemporary Management of Renal Cell Carcinoma: A Review for General Practitioners in Oncology.
August 30, 2024
Renal Cell Carcinoma A Review
August 28, 2024
Effect of race/ethnicity on survival in surgically treated intermediate/high risk non-metastatic clear cell renal carcinoma.
August 28, 2024
APOBEC3C-mediated NF-κB activation enhances clear cell renal cell carcinoma progression.
August 28, 2024
The influence of sex hormones on renal cell carcinoma.
August 26, 2024